Moteur de recherche d’entreprises européennes
Financement de l’UE (22,2 M €) : Alliance européenne pour un vaccin contre le VIH (EHVA) : une plateforme européenne pour la découverte et l’évaluation de nouveaux candidats vaccins prophylactiques … Hor01/01/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Alliance européenne pour un vaccin contre le VIH (EHVA) : une plateforme européenne pour la découverte et l’évaluation de nouveaux candidats vaccins prophylactiques et thérapeutiques
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses, 2. Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile, 3. Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines, and 4. Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure. EHVA project has developed a global and innovative strategy which includes: a) the multidisciplinary expertise involving immunologists, virologists, structural biology experts, statisticians and computational scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a number of African leading scientists/programs which will foster the testing of future EHVA vaccines through EDCTP
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 414 974 € |
| Association PAC-CI | 15 000,00 € |
| CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS | 0,00 € |
| CHU Hopitaux de Bordeaux | 0,00 € |
| 516 901 € | |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 707 843 € |
| EUROPEAN AIDS TREATMENT GROUP e. V. | 50 000 € |
| 0,00 € | |
| Erasmus Universitair Medisch Centrum Rotterdam | 310 000 € |
| FIT BIOTECH Oy | 965 184 € |
| 0,00 € | |
| Fred Hutchinson Cancer Research Center NON Profit Corporation | 310 879 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 722 162 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Imperial College of Science Technology and Medicine | 916 601 € |
| Inserm Transfert SA | 580 710 € |
| Institut National de la Sante et de la Recherche Medicale | 2 118 824 € |
| Instituto Nacional de Saúde | 15 000,00 € |
| 4 391 787 € | |
| 249 964 € | |
| Istituto Superiore DI Sanita | 537 250 € |
| Janssen Vaccines & Prevention B.V. | 34 845 € |
| Karolinska Institutet | 513 246 € |
| 992 500 € | |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 365 000 € |
| 515 000 € | |
| National Institute FOR Medical Research | 15 000,00 € |
| Sanofi Pasteur SA | 50 000 € |
| 0,00 € | |
| Stichting Amsterdam UMC | 0,00 € |
| Stichting Biomedical Primate Research Center | 1 000 018 € |
| Stichting International Aids Vaccine Initiative THE Netherlands | 93 749 € |
| THE General Hospital Corporation | 46 511 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 564 978 € |
| The University of Liverpool | 300 000 € |
| UNIVERSITAET BERN | 0,00 € |
| UNIVERSITAET REGENSBURG | 1 076 175 € |
| UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF | 616 500 € |
| 0,00 € | |
| UNIVERSITE DE LAUSANNE | 0,00 € |
| Uganda National Health Research Organisation | 24 985 € |
| Universite Grenoble Alpes | 567 638 € |
| Universite de Bordeaux | 0,00 € |
| Universite de Strasbourg | 0,00 € |
| 2 514 226 € | |
| VACCINE FORMULATION INSTITUTE(CH)Ltd. | 0,00 € |
| Vrije Universiteit Brussel | 75 074 € |
https://cordis.europa.eu/project/id/681032
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Agencia Estatal Consejo Superior de Investigaciones Cientificas - Financement de l’UE (22,2 M €) : Alliance européenne pour un vaccin contre le VIH (EHVA) : une plateforme européenne pour la découverte et l’évaluation de nouveaux candidats vaccins prophylactiques et thérapeutiques"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
